Asset Details
Do you wish to reserve the book?
Efficacy of a commercial vaccine PISCIVAC™ Irido Si against iridoviral disease and streptococcosis in Asian seabass (Lates calcarifer)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy of a commercial vaccine PISCIVAC™ Irido Si against iridoviral disease and streptococcosis in Asian seabass (Lates calcarifer)
Do you wish to request the book?
Efficacy of a commercial vaccine PISCIVAC™ Irido Si against iridoviral disease and streptococcosis in Asian seabass (Lates calcarifer)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy of a commercial vaccine PISCIVAC™ Irido Si against iridoviral disease and streptococcosis in Asian seabass (Lates calcarifer)
2024
Overview
Asian seabass (
Lates calcarifer
) is an economically important fish species in Southeast Asia. Iridoviral disease and streptococcosis are two of the major diseases in farmed Asian seabass. Here, we studied the efficacy of PISCIVAC™ Irido Si, a commercially available inactivated vaccine containing red seabream iridovirus (RSIV genotype II) and
Streptococcus iniae
antigens, against infectious spleen and kidney necrosis virus (ISKNV) genotype I and
S. iniae
infections in Asian seabass. In laboratory settings, the challenge of vaccinated fish with Vietnamese ISKNV genotype I strain showed 70–83% relative percent survival (RPS) at 21 days post-vaccination (dpv) and
S. iniae
challenge showed 75% or higher RPS at 7, 14, and 32 dpv. Also, the vaccine efficacy was confirmed at early vaccination stages (3 and 7 dpv) with an RPS of 85–97% against both pathogens and lasted for at least 74 and 348 dpv against ISKNV genotype I and
S. iniae
challenges, respectively. Furthermore, the vaccine was highly effective against challenges of ISKNV genotype I and
S. iniae
strains isolated in Thailand and Indonesia. These results suggest that the PISCIVAC™ Irido Si is useful for the prevention of iridoviral disease and streptococcosis in aquaculture of Asian seabass in ASEAN countries.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
